Athersys Inc ATHX:NASDAQ

Last Price$0.88NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/14/22

Today's Change+0.05(6.37%)
Bid (Size)$0.85 (12)
Ask (Size)$0.89 (6)
Day Low / High$0.81 - 0.88
Volume1.2 M

Athersys' Partner Reports Favorable Topline Results in Acute Respiratory Distress Syndrome Trial

2:37PM ET 8/06/2021 MT Newswires
Athersys (ATHX) said Friday that Healios, its partner in Japan, reported positive topline data from its clinical trial assessing the safety and efficacy of MultiStem cell therapy in patients with acute respiratory distress syndrome.

The trial in Japan has two patient groups, one with 30 pneumonia-induced ARDS subjects including treatment and registry groups, and the other with five COVID-induced ARDS subjects.

Both groups reported favorable topline results, including meeting the primary endpoint of ventilator-free days and the secondary endpoint of 90-day mortality. The data were in line with the results from Athersys's placebo-controlled study conducted in the US and UK.

MultiStem cell therapy has orphan regenerative medicine product designation in Japan for use in the treatment of ARDS.

Shares of Athersys were up 2.6% in afternoon trading.

Price: 1.58, Change: +0.04, Percent Change: +2.60